Package insert for Dawnrays cefoperazone sodium and tazobactam sodium for injection (4:1): indications, dosage, warnings, adverse reactions and storage.
Package insert for a compound injection containing cefoperazone sodium and tazobactam sodium in a 4:1 ratio, supplied as a white or off-white, hygroscopic crystalline powder in 1.0 g and 2.0 g strengths. It is indicated only for moderate to severe infections caused by beta-lactamase-producing bacteria that are resistant to cefoperazone alone and sensitive to the combination, including lower respiratory tract, urinary and genital tract, abdominal and pelvic infections, and sepsis and meningitis caused by the listed organisms.
The injection is given intravenously after dissolution and dilution, usually 2 g every 8 or 12 hours in adults, for a course generally of 7 to 10 days. The insert covers adverse reactions, contraindications, warnings about bleeding and coagulation disorders, use in pregnant and breastfeeding women, children and the elderly, drug interactions, overdose, pharmacology and toxicology, pharmacokinetics, storage, packaging, approval numbers and the marketing authorization holder, Dawnrays (苏州东瑞制药有限公司). This manual is written in Chinese.
| Strength (1.0 g) | Cefoperazone 0.8 g and tazobactam 0.2 g |
|---|---|
| Strength (2.0 g) | Cefoperazone 1.6 g and tazobactam 0.4 g |
| Appearance | White or off-white crystalline powder, hygroscopic |
| Shelf life | 24 months |
| Storage | Sealed, in a cool dark dry place, protected from light and not above 20 °C |
| Executive standard | YBH01542019 |
| Approval number (1.0 g) | 国药准字 H20193193 |
The powder is first dissolved and diluted, then given by intravenous infusion; each infusion takes 30 to 60 minutes.
Adults receive 2 g by intravenous infusion every 8 or 12 hours, usually for 7 to 10 days.
It should be kept sealed in a cool, dark and dry place, protected from light and at no more than 20 °C.
It must not be used in patients allergic to any of its components or to other beta-lactam antibiotics.